Biomatter
Founded Year
2018Stage
Seed VC - II | AliveTotal Raised
$7.73MLast Raised
$7.12M | 1 yr agoRevenue
$0000Mosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+25 points in the past 30 days
About Biomatter
Biomatter is a synthetic biology company that focuses on creating new proteins for various applications within the health and sustainable manufacturing sectors. The company offers a proprietary intelligent architecture platform that develops proteins with the capabilities of traditional engineering methods. Biomatter was formerly known as Biomatter Designs. It was founded in 2018 and is based in Vilnius, Lithuania.
Loading...
Biomatter's Product Videos
ESPs containing Biomatter
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The AI protein engineering platforms market includes computational platforms that leverage AI/ML to design and optimize proteins and peptides for therapeutic purposes or as therapeutic targets. These solutions combine structural biology insights with deep learning to predict protein folding, engineer desired properties, and accelerate drug development. Key capabilities include in silico protein de…
Biomatter named as Challenger among 15 other companies, including Ginkgo Bioworks, Cradle, and Arzeda.
Biomatter's Products & Differentiators
Generative protein design platform
Biomatter Designs has pioneered the technology for AI-driven generative protein design. The generative approach allows us to navigate immense protein space effectively and construct useful proteins towards desired value creating results right from the first atom. The platform is based on generative AI which the company has developed from the ground up for protein science. It is widely applicable and tested with different types of proteins and engineering goals, including rapid improvement of enzyme activity, stability and specificity, and effective design of specific protein binders for therapeutic and diagnostic applications. The platform can swiftly generate functional proteins vastly different from natural counterparts and unique in properties, while ensuring minimal experimental burden due to high accuracy of designs.
Loading...
Research containing Biomatter
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Biomatter in 9 CB Insights research briefs, most recently on Aug 22, 2025.
Aug 22, 2025 report
Book of Scouting Reports: Generative AI in Healthcare & Life Sciences
May 23, 2025
The AI in drug R&D market map
Jan 11, 2024
The generative AI in healthcare market map
Jan 8, 2024
4 applications of generative AI in drug R&D
May 9, 2023
7 applications of generative AI in healthcareMay 9, 2023
7 applications of generative AI in healthcareExpert Collections containing Biomatter
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Biomatter is included in 4 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
12,580 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Drug Discovery Tech Market Map
221 items
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Generative AI
2,793 items
Companies working on generative AI applications and infrastructure.
AI in drug discovery
524 items
Companies using AI to advance therapeutic discovery, categorized into: platforms (primary product is software) and discovery engines (primary product is therapeutics). Additional funnel descriptions reflect how companies are applying AI.
Latest Biomatter News
Aug 25, 2025
Neogen in Lansing to Advance Food Safety Using New Enzyme-based Products By Neogen Corp. in Lansing and Biomatter in Lithuania are partnering to create new enzyme-based products. // Stock photo Neogen Corp. in Lansing, a food safety solutions provider, has entered into an arrangement with Biomatter, an enzyme design company in Lithuania, to create new enzyme-based products. The agreement intends to blend Biomatter’s proprietary Intelligent Architecture platform and Neogen’s expertise in the field of analytical development and technology. Terms of the agreement were not disclosed. Biomatter’s Intelligent Architecture platform, based on AI and physical modelling, enables the design of enzymes with unique capabilities, dramatically expanding how they can be used in food safety-related applications. “This relationship marks a significant step forward in advancing food security,” says Jason Lilly, chief scientific officer at Neogen. “By combining our leadership and innovation in food testing and risk mitigation with Biomatter’s cutting-edge enzyme engineering capabilities, we’re unlocking new possibilities that can enhance detection, improve efficiency, and ultimately protect and enhance the quality and safety of the global food supply.” Laurynas Karpus, CEO of Biomatter, says, “It is a privilege to partner with Neogen to create new enzymes that will push the boundaries of food and animal safety solutions,” “Together, our teams aim to set new standards in the industry, making every step of the process more efficient, cost-effective, and ultimately more beneficial for the end user.” For more information, visit neogen.com/en/ and www.biomatter.ai . TAGS
Biomatter Frequently Asked Questions (FAQ)
When was Biomatter founded?
Biomatter was founded in 2018.
Where is Biomatter's headquarters?
Biomatter's headquarters is located at Zirmunu Street 139A, Vilnius.
What is Biomatter's latest funding round?
Biomatter's latest funding round is Seed VC - II.
How much did Biomatter raise?
Biomatter raised a total of $7.73M.
Who are the investors of Biomatter?
Investors of Biomatter include Metaplanet, Practica Capital, UVC Partners, Inventure, 70V and 5 more.
Who are Biomatter's competitors?
Competitors of Biomatter include Aqemia, Isomorphic Laboratories, Variational AI, Zymvol, Adaptyv Biosystems and 7 more.
What products does Biomatter offer?
Biomatter's products include Generative protein design platform.
Loading...
Compare Biomatter to Competitors
Cradle focuses on protein engineering in the biotechnology sector, using machine learning to optimize protein sequences. It provides tools for designing improved variants of target proteins, integrating laboratory data, and predicting performance to support research and development. Its solutions are relevant for biotech teams working on various applications, including therapeutics, enzymes, vaccines, peptides, and antibodies. It was founded in 2021 and is based in Amsterdam, Netherlands.
Isomorphic Laboratories serves as a digital biology company that operates in the pharmaceutical and artificial intelligence sectors. The company's main service is to use artificial intelligence, specifically machine learning, to transform and expedite the drug discovery process. The company primarily serves the pharmaceutical industry. It was founded in 2021 and is based in London, United Kingdom.
InstaDeep focuses on delivering artificial intelligence (AI)-powered decision-making systems for various enterprise sectors. The company offers solutions that leverage computing, deep learning, and reinforcement learning to address challenges in industries such as biology, logistics, electronic design, and energy. Its products and services are designed to help the capabilities of businesses by providing advanced AI tools and research insights. InstaDeep was formerly known as Digital Ink Group. It was founded in 2014 and is based in London, United Kingdom.
Endel specializes in creating personalized sound environments designed to reduce stress, improve sleep, and enhance productivity, utilizing neuroscience and circadian rhythm science. The company offers a range of products, including apps for iOS and Android, integrations with Alexa, and a standalone Apple Watch app, all featuring adaptive soundscapes that respond to real-time inputs such as time of day, weather, and heart rate. It was founded in 2018 and is based in Berlin, Germany.
Insilico Medicine focuses on artificial intelligence in drug discovery and development. The company provides artificial intelligence platforms for multi-omics target discovery, deep biology analysis, automated drug design, and predicting outcomes in clinical trials. The technologies are intended to assist in the process of discovering and developing new medications for various diseases. It was founded in 2014 and is based in New Territories, Hong Kong.
YDS Pharmatech is a company focused on drug discovery in the pharmaceutical industry. The company offers a platform for the design of new drug candidates, utilizing structure-based de novo drug design and evolutionary AI to accelerate the drug discovery process. YDS Pharmatech primarily serves the pharmaceutical industry. It was founded in 2020 and is based in Albany, New York.
Loading...